MDMA (Ecstasy) use during pregnancy is linked to poorer motor quality and lower milestone attainment in infants at 4 months, with a dose-response relationship: greater exposure corresponds to worse motor outcomes. This first prospective study of prenatal MDMA exposure in humans compared 28 women who used MDMA during pregnancy with 68 polydrug-using women who did not, controlling for confounding factors. MDMA-using mothers had fewer prior births and more health, work, and social problems. Exposed infants were more likely to be male. The findings suggest risk to the developing infant and indicate that continued follow-up is needed to determine whether early motor delays persist or resolve.
MDMA, commonly known as ecstasy, significantly influences both physiology and psychology by enhancing emotional connectivity and reducing anxiety. In a study involving 150 participants, those who consumed MDMA reported a 70% increase in feelings of empathy and trust. The drug's neurochemical effects involve the release of neurotransmitters that impact behavior, highlighting its potential therapeutic applications. Additionally, insights from cannabis and cannabinoid research suggest parallels in how these substances affect developmental psychology. Forensic toxicology continues to analyze their complex interactions within the body.
Mice given MDMA alone at a high dose showed temporary decreases in dopamine and tyrosine hydroxylase in the striatum and an increase in a marker of astrocyte activation (GFAP). When the methcathinones methylone or MDPV were combined with a lower MDMA dose, they did not affect dopamine or tyrosine hydroxylase levels but blocked the MDMA-induced increase in GFAP. Seven days after treatment, all measures returned to normal, indicating the changes were transient. Most drug groups caused an initial drop in body temperature followed by a gradual rise, but MDPV did not produce this pattern, suggesting it affects thermoregulation differently.